Wells Fargo Maintains Overweight on Ironwood Pharmaceuticals, Lowers Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Mohit Bansal has maintained an Overweight rating on Ironwood Pharmaceuticals (NASDAQ:IRWD) but has lowered the price target from $20 to $14.
March 01, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Wells Fargo maintains an Overweight rating on Ironwood Pharmaceuticals but lowers the price target from $20 to $14.
The reduction in price target by Wells Fargo, despite maintaining an Overweight rating, could lead to a negative short-term sentiment among investors, potentially causing a decrease in IRWD's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100